Cytomegalovirus human immunoglobulin.JPG

Cytomegalovirus human immunoglobulin

CLINICAL USE

Prophylaxis for renal transplant recipients at risk of primary cytomegalovirus (CMV) diseaseTreatment of CMV disease (usually with ganciclovir)

DOSE IN NORMAL RENAL FUNCTION

See local protocols

PHARMACOKINETICS

  • Molecular weight                           :150
  • %Protein binding                           :N/A
  • %Excreted unchanged in urine     : 0
  • Volume of distribution (L/kg)       :1
  • half-life – normal/ESRD (hrs)      :50

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Not dialysed. Dose as in normal renal function
  • HD                     :Not dialysed. Dose as normal renal function
  • HDF/high flux   :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD      :Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsCiclosporin: no effect on efficacy of CMV immunoglobulin

    ADMINISTRATION

    Reconstition

    Route

    IV peripherally or centrally

    Rate of Administration

    Comments

    Follow guidelines supplied by company

    OTHER INFORMATION

    Can give 10 mg IV chlorphenamine 1 hour before administrationMonitor for anaphylaxis, have epinephrine availableDo not mix with any other drugs or infusion fluids